Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jul 15, 2026 · Filed Jul 16, 2026
Gilead Sciences's Chief Comm & Corp Aff Officer sold $390K of Gilead Sciences shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$389,758
Shares × reported transaction price
69 days after results of May 7, 2026, 20 days before results of Aug 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $131.70 on Jul 15, 2026, 22% above its 52-week low and 15% below its high, little changed over the previous 30 trading days
52-week range $108.22 (Jul 18, 2025) to $155.80 (Feb 11, 2026), 49% of the way up, from 251 adjusted closes. 30 trading days earlier: $131.10 on Jun 1, 2026. Describes the past only, not a forecast
RSI 54, at its 200-day average, 1% above its 50-day average, 15% below the 52-week high, 20-day volatility 34% a year, against the S&P 500: +3 points over 1 month, −15 points over 3 months, −1 points over 6 months
From the adjusted closes up to Jul 15, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
FDA approved Trodelvy on Jun 24, 2026, 21 days before this trade.
New use approved (efficacy supplement). Active ingredient: Sacituzumab Govitecan-Hziy. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −3.7% | −0.6% | −3.1% |
| 30 days | +3.5% | +4.0% | −0.5% |
| 90 days | +17.2% | +3.8% | +13.4% |
Past results only. Not a forecast.
Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
2 tracked managers disclosed the same change for Q1 2026. From a 13F filed Aug 14, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
85 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.